Results of state purchases of SK-Pharmacia for 2024
According to the press service of SK-Pharmacia LLP, in 2024, every third Kazakhstani who received treatment under state programs received medicines purchased through the Single Distributor. This is 2 million patients across the country - from megacities to the most remote areas.
During the year, SK-Pharmacia centrally purchased 1,593 types of medicines and medical products. These are medicines for cardiovascular, oncological diseases, diabetes and other diseases that thousands of families face. All purchases were made for the needs of about 2,000 medical organizations across the country. Thanks to the centralized approach and competition in tenders, the state managed to save 50 billion tenge of budget funds.
Since the company's founding, the total savings amounted to 264.4 billion tenge. This is money that remained in the budget and can be used for other needs: additional volume, purchase of new equipment, improving the quality of services, etc.
The press service notes that SK-Pharmacia not only purchases, but also supports and develops domestic production. At the end of 2024, 94 long-term contracts were in effect with 35 domestic manufacturers. Within the framework of these agreements, 3,926 product names were purchased, of which 601 were medicines, 3,325 were medical devices. The share of purchases from Kazakhstani manufacturers amounted to 30% of the total volume, and excluding vaccines and orphan drugs - 37%. Thanks to this, there are more and more high-quality drugs "Made in Kazakhstan" on the market that meet international standards. Some diseases require very expensive treatment. For example, with a rare disease - mucopolysaccharidosis - one patient per year costs more than 110 million tenge. SK-Pharmacia LLP provides such patients with the necessary drugs despite the high price. This is a real chance for life.
As part of the development of healthcare infrastructure in 2024, tenders were announced for the purchase of 419 units of medical equipment. Contracts were signed for the supply of 396 units, the total amount is 57.4 billion tenge: from ventilators to MRI and diagnostic systems. Savings as a result of the purchase amounted to 3.2 billion tenge. This means that accurate diagnostics and timely treatment have become more accessible.